Last Price
2.42
Today's Change
-0.02 (0.81%)
Day's Change
2.029 - 2.48
Trading Volume
2,206,193
Market Cap
33 Million
Shares Outstanding
14 Million
Avg Volume
1,665,163
Avg Price (50 Days)
1.24
Avg Price (200 Days)
1.47
PE Ratio
-3.18
EPS
-0.76
Earnings Announcement
03-Mar-2025
Previous Close
2.44
Open
2.09
Day's Range
2.03 - 2.48
Year Range
1.04 - 3.05
Trading Volume
2,216,509
1 Day Change
-0.82%
5 Day Change
100.00%
1 Month Change
101.67%
3 Month Change
79.26%
6 Month Change
58.17%
Ytd Change
30.81%
1 Year Change
43.20%
3 Year Change
-42.52%
5 Year Change
-53.46%
10 Year Change
-53.73%
Max Change
-85.62%
No result.
Sector: Healthcare - Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Description:
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.